echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Significantly prolong the life combination therapy of specific prostate cancer patients to reach the primary clinical endpoint of phase 3

    Significantly prolong the life combination therapy of specific prostate cancer patients to reach the primary clinical endpoint of phase 3

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 3, 2021, Bayer and Orion announced that a phase 3 clinical trial of the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) has reached the primary endpoint


    Prostate cancer is the second most common cancer in men in the world and the fifth leading cause of cancer deaths in men


    Nubeqa has a unique chemical structure, can bind to androgen receptor with high affinity and exhibits strong antagonistic activity, inhibiting the transfer of androgen receptor to the nucleus and its mediated gene expression, thereby inhibiting the proliferation of prostate cancer cells Purpose


    Note: The original text has been deleted

    Reference materials:

    [1] Phase III Investigational Trial of Nubeqa® (darolutamide) in Combination with Docetaxel and Androgen Deprivation Therapy (ADT) Meets Primary Endpoint of Significantly Increasing Overall Survival (OS) in Patients with mHSPC.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.